INTRODUCTION AND OBJECTIVES:
Benign prostatic hyperplasia (BPH) is a disease characterized by stroma hyperplasia. Our previous studies, stromaeepithelium ratios and collagen deposition were prevalent in rapidly-progressed BPH patients (age 50 years old). Meanwhile, we also detected that senescent prostatic epithelial cells were associated with the number of fibriblast. The present study mainly investigates if senescent prostatic epithelial cells could influence the progression of BPH through inducing the growth of fibroblast.
METHODS: Formalin-fixed paraffin-embedded (FFPE) prostate tissues obtained from three groups of patients (7 cases in each) were included in this study: (1) prostate tissues of patients with rapidlyprogressed BPH, aged 50 years, obtained during the transurethral resection of the prostate (TURP); (2) age-matched prostate tissues, acquired from patients with bladder cancer, aged 50 years, who underwent radical cystectomy and prostatectomy and (3) prostate tissues of elderly patients with BPH, aged !70 years, obtained during TURP. Senescent epithelial cells were labeled by p16INK4a (senescent related gene) through immunohistochemistry. In vitro, we used doxorubicin to modeling epithelial cells (BPH-1 cells) aging. After 2 days, culture of BPH-1 treated with doxorubicin, the conditioned media was harvested and used to evaluate the proliferation of primary prostatic stromal cells by Cell Counting Kit. Quantitative PCR was used to identify cytokines secreted by the BPH-1 cells treated with doxorubicin.
RESULTS: p16INK4a stains almost in prostatic epithelial cells, and it was expressed stronger in rapidly-progressed BPH than in the other two groups. The conditioned media could accelerate the proliferation of primary prostatic stromal cells. Cytokines CCL-5, VEGF, IL-10, IL-1a, IL-4, IL-6, IL-8 were increased in senescent BPH-1 after being treated by doxorubicin. Senescent prostatic epithelial cells could influence the rapid progression of BPH by these cytokines.
CONCLUSIONS: Senescent prostatic epithelial cells may play a role in the progression of BPH through facilitating fibroblast proliferation.
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MP06-10 INHIBITION OF PROSTATE SMOOTH MUSCLE CONTRACTION BY NAV2729 SUGGESTS PROMOTION OF PROSTATE SMOOTH MUSCLE CONTRACTION BY ADP RIBOSYLATION FACTOR 6
Qingfeng Yu*, Christian Gratzke, Paul Kuppermann, Annika Herlemann, Alexander Tamalunas, Yiming Wang, Beata Rutz, Anna Ciotkowska, Raphaela Waidelich, Christian G. Stief, Martin Hennenberg, Munich, Germany INTRODUCTION AND OBJECTIVES: In benign prostatic hyperplasia, prostate smooth muscle contraction drives urethral obstruction, resulting in lower urinary tract symptoms. Inhibition of prostate contraction is an important strategy for medical therapy, but available options show limited efficacy. Development of future options with higher efficacy requires identification of novel targets and adequate understanding of contractile mechanisms, which are, however, still incompletely understood. Recent findings suggested a possible role of the monomeric GTPase ADP ribosylation factor 6 (ARF6) for smooth muscle contraction in the human prostate. Here, we examined effects of the ARF6 inhibitor NAV2729 on GTPase activities and contraction of human prostate tissues.
METHODS: Human prostate tissues were obtained from radical prostatectomy (n[63 patients). Contraction of prostate strips were studied in an organ bath. GTPase activities were examined by pulldown assays. Relationships between ARF6 expression and degree of BPH were studied by RT-PCR and Western blot. Actin organization was studied in cultured stromal cells (WPMY-1).
RESULTS: Electric field stimulation induced frequencedependent contractions of prostate strips, which were significantly inhibited by NAV2729 (5 µM) (p<0.04 between NAV2729 and controls). Noradrenaline and the a1-agonists phenylephrine and methoxamine induced concentration-dependent contractions of human prostate strips, which were significantly inhibited by NAV2729 (p<0.001 for noradrenaline, p<0.002 for phenylephrine, p<0.001 for methoxamine). RT-PCR and Western blot analyses revealed a positive correlation between prostatic ARF6 expression and content of prostate-specific antigen (PSA), suggesting upregulation of ARF6 with increasing degree of BPH (r[0.657 for mRNA, r[0.762 for protein expression). NAV2729 inhibited ARF6 activity, but not other GTPases (ARF1, RhoA, Rac1) in prostate tissues and in WPMY-1 cells, suggesting a high degree of specificity of NAV2729 for ARF6. This was paralleled by breakdown of actin organization in WPMY-1 cells.
CONCLUSIONS: NAV2729 inhibits a1-adrenergic smooth muscle contraction and ARF6 activity in the hyperplastic prostate. Urodynamic effects of NAV2729 appear possible in vivo. Our findings point to a role of ARF6 for prostate smooth muscle contraction. A function of ARF6 in promoting smooth muscle contraction has never been described before for any organ. ARF6 may promote a1-adrenergic prostate smooth muscle contraction by promoting actin polymerization. At the same time, we found that the condition of autophagy was also increased in BPH fibroblast cells. This research mainly investigates that autophagy could influence the progression of BPH through accelerating myofibroblast phenotype, proliferation and suppress its apoptosis in BPH tissues.
METHODS: Paraffin-embedded prostate specimens were collected, of which including early-progressed BPH samples (age 50, obtained from patients undergoing transurethral resection of the prostate, TURP), age-matched prostate samples (age 50, acquired from bladder cancer patients who underwent radical cystectomy and prostatectomy) and elderly BPH samples (age!75, obtained from patients undergoing TURP). LC3 protein was assessed by immunohistochemistry in these samples. a-smooth muscle actin and collagen I (Myofibroblast phenotype related genes), cleaved-PARP (apoptosis related gene), p62(autophagy related gene) were detected by western blotting (WB) in primary prostatic stromal cell (Prsc 49 and 53) treated with chloroquine (CQ, autophagy inhibitor). After Prsc
